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FLUORESCENT 1-
PEPTIDYLAMINOALKANEPHOSPHONATE 
DERIVATIVES 
2 
Tagging these inhibitors with fluorescent labels will render 
them excellent tools for studying the distribution of serine 
proteases as well as measuring their quantities in natural 
killer cells, lymphocyte cells, and all other types of cells and 
BACKGROUND OF THE JNVENITON 
1. Field of the Invention 
5 biological systems. 
This invention relates to a novel class of fluorescent 
peptidyl derivatives of aromatic diesters of 
1-aminoalkanephosphonic acid useful for selectively inhib- 10 iting elastases, selectively inhibiting chymotrypsin-like 
enzymes, selectively inhibiting trypsin-like enzymes or for 
generally inhibiting serine proteases of many classes. 
2. Description of the Related Art 
Serine proteases play critical roles in several physiologi- 15 
cal processes such as digestion, blood coagulation, comple-
ment activation, fibrinolysis, viral infection, fertilization, 
and reproduction. Serine proteases are not only a physi-
ological necessity, but also a potential hazard if they are not 
controlled. Uncontrolled proteolysis by. elastases may cause 2o 
pancreatitis, emphysema, rheumatoid arthritis, bronchial 
inflammation and adult respiratory distress syndrome. 
Human polymorphonuclear leukocyte elastase may also be 
involved in blistering. Accordingly, potent and specific 
inhibitors of these proteases tagged with fluorescent mol- 25 
ecules can be used to detect, localize, and quantify these 
enzymes in different types of cells and biological systems. 
Serine proteases inhibited by these fluorescent compounds 
can be detected at the single cell level. 
Many classes of phosphorus containing compounds have 30 
been prepared for use as inhibitors of serine proteases. One 
useful class reported by Oleksyszyn and Powers are peptidyl 
derivatives of a-aminoalkylphosphonate diphenyl esters 
(Irreversible Inhibition of Serine Proteases by Peptide 
Derivatives of ( a-aminoalkyl)phosphonate Diphenyl Esters, 35 
Oleksyszyn, J. and Powers, J. C., Biochemistry, 1991, 30, 
485-493). Other members of the class were described by 
Bartlett, P.A. and Lamden, L.A., Bioorg. Chem., 1986, 14, 
356-377 and Lamden, L. A. and Bartlett, P. A., Biochem. 
Biophys. Res. Commun., 1983, 112, 1085-1090. These com- 40 
pounds are useful inhibitors for the serine proteases 
elastases, chymotrypsin, chymotrypsin-like, trypsin, 
trypsin-like, blood coagulation enzymes, kallikrein, 
plasmin, thrombin, and granzymes. Another class of diphe-
nyl peptide phosphonate esters was published by Olek- 45 
syszyn et al., 1994 (Novel Amidine-Containing Peptidyl 
Phosphonates as Irreversible Inhibitors for Blood Coagula-
tion and Related Serine Proteases Oleksyszyn, J., Boduszek, 
B., Kam, C.-M., and Powers, J. C., J. Med. Chem. 1994, 37, 
226-231). This class included peptides with C-terminal 50 
phosphonate residues related to ornithine, lysine, arginine, 
or containing a C-terminal diphenyl ester of a-amino-a-( 4-
amidinophenyl)methanephosphonate ((4-AmPh)Gly1'(0Ph) 
2 ) or a-amino-a-( 4-amidinophenylmethyl) 
methanephosphonate ((4-AmPhef(Oph)2). These peptide 55 
phosphonates are specific and potent inhibitors of trypsin, 
thrombin, kallikrein, trypsin-like enzymes, coagulation 
enzymes, and granzymes. A few other arginine and ornithine 
analogs and peptidyl phosphonates containing ( a-amino-y-
methoxybutyl)phosphonyl or (a-amino-n-hexyl)phosphonyl 60 
residues at the P 1 site have been reported to be inhibitors of 
trypsin and thrombin (Fastrez et al., Tetrahedron Lett., 1989, 
30, 6861-6864; Cheng et al., Tetrahedron Lett., 1991, 32, 
7333-7336; Wang et al., Tetrahedron Lett., 1992, 33, 
7667-7670; and Hamilton et al., Tetrahedron Lett., 1993, 34, 65 
2847-2850). None of the diphenyl peptide phosphonate 
esters mentioned above has fluorescent label attached to it. 
BRIEF SUMMARY OF THE INVENTION 
We have found that diphenyl 
1-pepidylaminoalkanephosphonate esters tagged with fluo-
rescent groups such as fluorescein or sulforhodamine 101 
are potent inhibitors of elastases, chymases, and other serine 
proteases. These fluorescent compounds are made by cou-
pling fluorophores to peptidylphosphonates using spacer 
groups between the peptide and the fluorophore. The spacer 
groups are inserted in order to prevent unfavorable steric 
interactions between the fluorophore and the active site of 
the protease. These compounds can be used to irreversibly 
label discrete granule-like regions of the natural killer (NK) 
cells. These fluorescent peptide phosphonates can be used to 
selectively inhibit serine proteases within whole cells. These 
fluorescent compounds can also be used to localize serine 
proteases inside cellular granules. These fluorescent com-
pounds can also be used to selectively or generally inhibit 
serine proteases either in vitro or in biological systems. The 
properties of these fluorescent compounds indicate that they 
will be excellent tools for the study of the distribution of 
serine proteases in lymphocytes and their role during cyto-
toxic T-lymphocyte killing. Use of these inhibitors with 
different peptide sequences with varying specificities and 
different fluorophores will allow the simultaneous detection 
of different proteases in cytotoxic lymphocytes as well as in 
other cells and biological systems. 
It is an object of this invention to find a novel group of 
specific fluorescent inhibitors for elastase, chymotrypsin, 
trypsin, and other serine proteases of similar substrate speci-
ficity and for serine proteases in general. Inhibitors are 
compounds that can reduce or eliminate the catalytic activity 
of the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 
amino acid residue on the carbonyl side of the split bond (P 1 
residue) is Lys, or Arg. Elastase and elastase-like enzymes, 
on the other hand, cleave peptide bonds where the P 1 amino 
acid is Ala, Val, Ser, Leu and other similar amino acids. 
Chymotrypsin and chymotrypsin-like enzymes hydrolyze 
peptide bonds where P 1 amino acid is Trp, Tyr, Phe, Met, 
Leu or other amino acid residues which contain aromatic or 
large alkyl side chains. All of the above enzymes have 
extensive secondary specificity and recognize amino acid 
residues removed from the P 1 residue. 
It is a further object of this invention to define new 
fluorescent protease inhibitors, especially inhibitors for chy-
motrypsin and chymotrypsin-like enzymes, elastases, blood 
coagulation enzymes, tryptases, trypsin-like enzymes, 
kallikrein, and granzymes. Such inhibitors could be used to 
identify and localize new proteolytic enzymes encountered 
in research. The inhibitors of this invention would be useful 
for studying the role and the distribution of serine proteases 
found in cytotoxic T lymphocyte and natural killer cells. 
These inhibitors are useful for controlling, detecting, and 
measuring the active serine proteases involved in tumor 
invasion, blood coagulation and various inflammatory con-
ditions mediated by serine proteases. The inhibitors of this 
invention would be useful for studying the distribution and 
role of natural killer and cytotoxic lymphocyte serine pro-
teases. 
It is yet another object of this invention to define a novel 
group of specific inhibitors useful in vitro for inhibiting 
5,681,821 
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trypsin, elastase, chymotrypsin and other serine proteases of 
similar specificity. These inhibitors can be used in research 
to detect and measure undesired serine proteases found in all 
cells, tissues, and fluids. 
Fluor is selected from the group consisting of 
These and other objects are accomplished by the present 
invention which defines novel fluorescent peptidyl deriva-
tives of aryl diesters of 1-arninoalkanephosphonic acids. 
These fluorescent phosphonate derivatives are potent inhibi-
tors of serine proteases including chymotrypsin-like 
enzymes, trypsin-like enzymes, elastase-like enzymes, and 
other enzymes with other substrate specificities. The fluo-
rescent peptide phosphonates are stable in buffer or plasma, 
and inhibit the serine proteases to give stable inhibited 
enzyme derivatives that can easily be detected using con-
focal microscopy and other ways. The fluorescent peptide 
phosphonates can be used in both in vitro and in vivo. 
DETA1LED DESCRIPITON OF THE 
INVENTION 
5 
10 
15 
20 
25 
Fluorescent peptidyl derivatives of aryl diesters of 
1-aminoalkanephosphonic acids have been found to be 
excellent inhibitors of several serine proteases including 
human leukocyte elastase, porcine pancreatic elastase, 
bovine chymotrypsin, and bovine trypsin. The fluorescent 
diesters of 1-peptidylarninoalkanephosphonic acids are ana-
logs of natural ex-amino acids and are designated by the 
generally accepted three letter abbreviations for the amino 
acid followed by the superscript P. For example diphenyl 
1-(6-(5-fluoresceinylthiocarbamoylarnino )caproylamino) 30 
ethanephosphonate which is related to alanine is abbreviated 
as FTC-Aca-AlaP(OPh) 2 • FTC is 
5-fluoresceinylthiocarbamoyl and Aca is 6-arninocaproyl. 
(a) 
HO 
Complete structure ofFTC-Aca-AiaP(OPh)z 
50 
The novel fluorescent peptidyl phosphonate inhibitors and 
related compounds contain a fluorophore (Fluor) bonded to 55 
the peptidyl phosphonate moiety through a spacer group and 
they have the following general structure: 
R 
l /oz Fluor-T-Spacer-AA3-AA2-~ P 
H ll'oz1 
0 
60 
y 
HO 
(5-Substitued Fluorescein) 
y 
0 
(6-Substituted Fluorescein) 
-continued 
65 (5-Substituted Tetramethylrhodamine) 
or an acceptable salt, wherein 
0 
0 
(a) 
(b) 
(c) 
5,681,821 ' 
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(d) 
(6-Substituted Tetramethylrhodamine) 
(e) 
(5-Substituted Texas Red) 
(f) 
(6-Substituted Texas Red) 
(g) an aromatic fluorescent group with an emission 
maximum of 350 to 700 nm 
5 
10 
15 
20 
25 
30 
35 
40 Y is selected from the group consisting of H, COOH, and 
S03H, 
T is selected from the group consisting of -NH-CO-, 
-NH-CS-, -CO-, and -S02-, 
~Kcrh ~ 
(a) a single bond, 
(b) -NH-CH2-CH2-CH2-CH2-CH2-CO-, 
( c) -NH-CH2-CH2-CH2-CH2-CH2-CO-
NH-CH2-CH2-CH2-CH2-CH2-CO-, 
( d) an organic structure which is 3-24 A long and 50 
including a backbone comprising at least one mem-
bcr of the group consisting of -CH2-CH2-, 
HO OH 
(Lactone Form) 
6 
-CO-NH-, -NH-CO-, -CH2-CO-, 
-CH2-NH-, -NH-CH2-, and -C6H4-, 
AA3 and AA2 are the same or different and are selected 
independently from the group consisting of 
(a) a single bond, 
(b) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, proline, methionine, methionine 
sulfoxide, methionine sulfone, phenylalanine, 
tryptophan, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, 
norleucine, norvaline, alpha-arninobutyric acid, 
citrulline, hydroxyproline, ornithine, and 
homoarginine, and 
(c) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, 
R is selected from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
selected from the group consisting of glycine, 
alanine, valine, leucine, isoleucine, proline, 
methionine, methionine sulfoxide, methionine 
sulfone, phenylalanine, tryptophan, serine, 
threonine, cysteine, tyrosine, asparagine, glutarnine, 
aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
ornithine, and homoarginine, and 
(b) phenyl substituted with B, benzyl substituted with 
B on the phenyl, 
B is selected from the group consisting of amidino 
(-C(=NH)NH2 ), guanidino (-NH-C( NH) 
NH2 ), isothiureido (-S-C(=NH)NH2 ), and 
amino, 
Z and Z1 are the same or different and are selected 
independently from the group consisting of phenyl, 
phenyl substituted with J, phenyl disubstituted with J, 
and phenyl trisubstituted with J, and 
J is selected from the group consisting of halogen, C1-6 
alkyl, C1-6 perfiuoroalkyl, C1-6 alkoxy, N02 , and 
CN. 
The fluorophores used in this invention are those well 
known in the art of fluorescence. Examples of fluorophores 
include sulforhodamine (Texas Red), tetramethylrhodarnine, 
rhodamine X, and fluorescein as well as their derivatives and 
tautomeric forms (see structures below). The fluorescent 
group can also be any fluorophore which can be attached to 
the spacer and can emit in the range of 350-700 nm. 
HO 0 
(OpeuFonn) 
coo-
0 
Floorescein 
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-continued 
(Lactone Form) (Open Form) 
Tetramethylrhodamine 
(Lactone Form) (Open Form) 
RlxxlamineX 
Fluorescent peptidyl derivatives of aryl diesters of 30 
1-aminoalkanephosphonic acids inhibit serine proteases by 
reaction with the active site serine to form phosphonylated 
enzymes, which due to similarity of phosphorus atom to the 
tetrahedral intermediate formed during peptide hydrolysis, 
show remarkable stability. The enzyme catalytic apparatus is 35 
required to activate the phosphorus atom for nucleophilic 
substitution and reaction with enzyme. The activation is 
mainly due to precise interaction with the S1 pocket of 
various serine proteases. The following figure shows the 40 
-continued 
S1 Active Site 
Sl Ser195 
R I 
R-CO-NH-bH-P/O H-Hiss7 
11'-o-
o. 
H ,• '' H oxyanion 
I I hole 
N N 
reaction course of a phosphonate with a serine protease. The Peptides with a C-terminal phosphonate residue which is 
phosphonate first binds to the enzyme (below left) and then an analog ofvaline (e.g. ValP(OPhh) are potent and specific 
reacts to form a covalent bond with the active site serine irreversible inhibitors of elastase and elastase-like enzymes. 
residue (below right). Slow aging can take place with loss of The peptides with C-terminal phosphonate residues related 
the phenoxy group (below center). 45 to phenylalanine, other aromatic amino acids or amino acids 
Substrate 
Binding Site 
R 
Ser195 
I 
Active Site 
O-H--·Hiss1 
I ,...oPh 
R-CO-NH-CH-P 
11'-oPh 
0 
S1 Active Site 
__fl Ser195 
R I 
R-CO-NH-bH-P/O H-Hiss7 
11'-0Ph 
H 
•• o .•• H 
oxyanion 
I I hole 
N N 
Aging> 
with long aliphatic side chains are potent and specific 
inhibitors of chymotrypsin and chymotrypsin-like enzymes. 
The peptides with C-terminal phosphonate residues related 
to ornithine, lysine, arginine or containing a C-terminal 
50 diphenyl ester of amino(4-amidinophenyl) 
methanephosphonate ((4-AmPh)Gly(Oph):i) or amino(4-
amidinophenylmethyl)methanephosphonate ((4-AmPhel 
(Oph):i) are specific and potent inhibitors of trypsin and 
55 
trypsin-like enzymes. 
Additional specificity as well as increased activation 
toward reaction with the enzyme can be introduced into the 
inhibitor molecule by variation of the amino acid sequence 
in the peptide portion of the structure. In fact them is a good 
agreement between the sequence of enzyme substrates such 
60 as a peptidyl p-nitroanilides or benzylthioesters and the 
sequence of an effective peptidyl phosphonate inhibitor. The 
best inhibitors have the sequence of the best peptidyl 
p-nitroanilide substrate for a particular enzyme. For 
example, a potent inhibitor for chymotrypsin and 
65 chymotrypsin-like enzymes is FTC-Aca-Phe-Leu-PheP 
( OPhh (see Table I) which has an amino acid sequence that 
is analogous to Suc-Phe-Leu-Phe-SBzl, an excellent sub-
5,681,821 
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60 minutes of incubation. These initial rates were used as v 0 
in the calculation of the inhibition rate constants. 
Inhibitor Potency 
The :fluorescent compounds were evaluated as inhibitors 
5 of chymotrypsin, PPE, and HLE and were found to be potent 
and very specific with inactivation rate constants (k,,bsj(I)) 
as high as 9,500 ~1s-1 (Table I). The specificity of these 
phosphonate inhibitors is dependent upon the amino acid 
strate for these enzymes. With human leukocyte and porcine 
pancreatic elastases, the best inhibitor (FfC-Aca-Ala-Ala-
AlaP(OPh):J has an amino acid sequence similar to Suc-
Ala-Ala-Ala-NA and Boe-Ala-Ala-Ala-NA, two excellent 
substrates for porcine pancreatic elastase, and to the chlo-
romethyl ketone, Ac-Ala-Ala-AlaCH2Cl, a, good inhibitor of 
human leukocyte elastase. Clearly it is possible to design 
good phosphonate inhibitors for serine proteases based on 
the peptide sequences found in other potent reversible and 
irreversible inhibitors for those same serine proteases 10 
reported in the literature. In this application, we disclose 
methods of attached fluorescent groups to those potent 
phosphonate inhibitors. 
sequence in the tripeptide portion of the inhibitor. In each 
case, the amino acid sequence was chosen based on the 
specific sequence of a good substrate or inhibitor for the 
target enzyme. For example, previous studies showed that 
human Q31 chymase, cathepsin G, and related 
chymotrypsin-like enzymes have significant hydrolysis The following compounds are representatives of the 
invention: 
Di phenyl l-( 6-( 5-:fluoresceneinylthiocarbamoylamino) 
caproylalanylal anylamino )-3-(meth yl thi o) 
propanephosphonate 
Diphenyl 1-( 6-(5-fl uoresceinylthiocarbamoylamino) 
caproylalanylalanylamino )ethanephosphonate 
15 activity toward Suc-Phe-Leu-Phe-SBzl and were potently 
inhibited by the corresponding peptide chloromethyl ketone, 
Suc-Phe-Leu-Phe-CH2Cl. The Phe derivative compound 
(3), which has the same amino acid sequence inhibited 
chymotrypsin very potently (k,,bsj(I)=9,500 M-1s-1 ) and 
20 600 times faster than it inhibited HLB (k,,bsj(I)=l6 M-1 s-1 ). 
Diphenyl 1-(6-(5-fluoresceinylthiocarbamoylamino) 
ca pro ylphe n ylal anylleu cylamin o )-2-
phenylethanephosphonate 
Chymotrypsin was also inhibited by FI'C-Aca-Ala-Ala-
Met1'(0Ph)z (1) more effectively (kobs,/(1)=190 M-1s-1) 
than HLE and PPE (kobsi(I)=22 and 13 M-1s-1 , 
respectively). Likewise, the p-nitroanilide substrates Suc-Diphenyl 1-(6-(5-fluoresceinylthiocarbamoylamino) 
caproylamino )( 4-arnidinophenyl)methanephosphonate 
Diphenyl 1-(6-(4(or 2)(9-(2,3,6,7,12,13,16,17-octahydro-
1H,5H, 11H,15H-xantheno(2,3,4-ij :5 ,6, 7-i'j ') 
diq uinolizinyl-18-i um) )3 (or 5) sulfo-1-
phenylsulfonamido )caproylphenylalanylleucylamino )-2-
phenylethanephosphonate, hydroxide, inner salt. 
Enzyme Kinetics 
25 Ala-Ala-Ala-NA and Boe-Ala-Ala-Ala-NA were hydro-
lyzed effectively by PPE and peptide chloromethyl ketones 
such as Ac-Ala-Ala-Ala-Ala-CH2Cl are good inhibitors of 
HLB. Compound (2), FI'C-Aca-Ala-Ala-AlaP(OPh)z, as 
expected inhibited PPB and HLE with k0 b,,j(I) of 22 and 41 
30 M-1s-1, respectively, but did not inhibit chymotrypsin. 
Inactivation rates of serine proteases by fluorescent pep-
tidylphosphonates were measured by the incubation method. 
In each case the inactivation experiment was preceded by an 
enzyme assay in which the hydrolysis of peptide 35 
p-nitroanilide substrates, catalyzed by chymotrypsin, PPB, 
HLE, and trypsin was measured in O. lM Hepes and 0.5M 
NaCl (0.0lM CaC12 for trypsin), pH 7.5 buffer containing 
5-10% Me2SO at 25° C. Stock solutions of substrates were 
prepared in Me2SO (20 mM) and stored at -20°. C. Final 40 
substrate concentrations were 0.24 mM, Chymotrypsin 
activity was assayed with Suc-Val-Pro-Phe-NA. PPE was 
assayed with Sue-Ala-Ala-Ala-NA. HLB was assayed with 
MeO-Suc-Ala-Ala-Pro-Val-NA and trypsin was assayed 
with Z-Arg-NA. The initial rates of hydrolysis were mea- 45 
sured at 410 nm (€410=8800 M-1cm-1) on a Beckman 35 
spectrophotometer after 25-50 µL of an enzyme stock 
solution was added to a cuvette containing 2.0 mL of buffer 
and 25 µL of substrate. 
Each inhibition reaction was initiated by adding a 50 µL 50 
aliquot of inhibitor (100-5000 µMin Me2SO) to 0.5 mL of 
The presence of the fluorescein fluorophore in these 
inhibitors resulted in either better or the same inhibitory 
potency compared to their nonfluorescent analogs. For 
example, with chymotrypsin, the presence of the fluoro-
phores increased the potency of these inhibitors. The fluo-
resceinylated Phe analog (3) inhibited chymotrypsin very 
potently with k,,bsj(I) of 9500 M-1s-1, while the nonfluo-
resceinylated analog, Z-Phe-Leu-PheP(OPh)2 (7), inhibited 
chymotrypsin but less potently with k,,bsj(I) of 110 M-1s-1• 
Compound (1), FI'C-Aca-Ala-Ala-Met1'(0Ph)2, was found 
to be a better inhibitor of chymotrypsin and HLE, kobsj(I) 
=190 and 22 M-1s-1 respectively, than Boc-Ala-Ala-Met1' 
(OPh)z (5), k.ot,sj(I)=3 and 2 M-1s-1, respectively. In con-
trast to FI'C enhancement of the inhibitory potency of the 
chymotrypsin-directed inhibitors with chymotrypsin, the 
presence of FI'C did not alter the efficacy of the elastase-
directed inhibitor with the two elastases. FI'C-Aca-Ala-Ala-
A1a1'(0Ph)2 (2) and its analog Z-Ala-Ala-Ala1'(0Ph)z (6), 
inhibited HLB with almost equal rate constant values, kobsj 
(!)=38 and 41 M-1 s-1 , respectively. Compound (2) also 
showed similar efficacy with PPE as compound (6), k0 bsj 
(!)=22 and 30 M-1s-1 , respectively. Fluorescent Met and Phe 
derivatives (1) and (3) are better inhibitors of PPE (k,,1nj 
(!)=13 and 16 M-1s-1, respectively) compared to their 
nonfluorescent analogs, compounds (5) (k.ot,sj(I)=3 M-1s-1) 
and (7) (no inhibition). The fluoresceinylated Ala analog, 
Compound (2), on the other hand, showed almost the same 
inhibitory effect with PPB as did its nonfluorescent analog, 
Z-Ala-Ala-AlaP(OPh)z (6), k,,bsj(I)=22 and 30 M-1s-1, 
a 0. lM Hepes, 0.5M NaCl (0.0 lM CaC12 for trypsin), pH 7 .5 
buffer containing 50 µL of a stock enzyme solution at 25 ° C. 
The enzyme stock solutions were 20 µM chymotrypsin, 
trypsin, and PPE in 1 mM HCl (pH 3), and 0.4-4 µM HLE 55 
in 0.25M NaAc and lM NaCl at pH 5.5. All the enzyme 
stock solutions were stored at -20° C. prior to use. Aliquots 
(25 µL) were withdrawn at various intervals and the residual 
enzymatic activity was measured spectrophotometrically as 
described above. Pseudo first-order inactivation rate con-
stants (kobs) were obtained from plots of ln v /v 0 vs time and 
had correlation coefficients greater than 0.98. Each k.ot,sd was 
calculated from 5-10 activity determinations which 
extended to 2-3 half lives. Control experiments were carried 
out in the same way as described above except Me2SO was 65 
added in place of the inhibitor solution in Me2SO. The initial 
rates of substrate hydrolysis did not change during the first 
60 respectively. 
Addition of the Texas Red fluorophore resulted in a less 
effective compound in comparison with an analogous com-
pound with the FTC-fluorophore. The TXR-labeled 
derivative, TXR-Aca-Phe-Leu-PheP(OPh)z (4) showed less 
inhibition with all three enzymes compared to FI'C-Aca-
Phe-Leu-PheP(OPh)z (3). However, when TXR-Aca-Phe-
Leu-Phe(OPh)z (4) was compared with nonfluorescent 
5,681,821 
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Z-Phe-Leu-PheP(OPhh (7), the effects varied with the clif-
ferent enzymes. Inhibition of chymotrypsin was less with 
TXR-Aca-Phe-Leu-PheP(OPhh (4) while inhibition of .HLE 
and PPE was greater (fable I). 
From the results discussed above, it can be concluded that 5 
attaching the :fluorophores in these phosphonate inlubitors 
resulted in either a similar or equal inhibitory potency with 
.HLE and PPE. In the case of chymotrypsin, the presence of 
the FfC fluorophore increased the potency of these inhibi-
tors substantially, an observation that implies interactions 10 
between this fluorophore and chymotrypsin. It is also clear 
that the specificities of these :fluorescent compounds are 
parallel to those of nonfluorescent analogs and are depen-
dent on the sequences of the peptide portions. 
TABLE I 
12 
protease inhibitor soybean trypsin inhibitor. In the latter 
experiments, the cells were fixed and permeabilized before 
the macromolecular inhibitor was used. Thus the fluorescent 
phosphonate compounds offer technical advantages over 
previous approaches. The new reagents also have far greater 
specificity: soybean trypsin inhibitor inactivated both 
tryptases and chymases of cytotoxic lymphocytes whereas 
the FTC-Aca-Ala-Ala-Met1'(0Phh inactivated RNK-16 
chymase and little Asp-ase or tryptase granule protease 
activities. 
Synthesis 
The diphenyl 1-aminoalkanephosphonate esters are syn-
thesized from the appropriate aldehyde, benzyl carbamate, 
and triphenyl phosphite using previously a reported method 
Inhibition of Serine Proteases by Fluorescent Peptide Phosphonates• 
Inhibitor (I) (rnM) Chymotrypsin PPE HLE 
FfC-Aca-Ala-Ala-Met"(Oph),(1) 8.3 190 13 22 
FfC-Aca-Ala-Ala-AlaP (0Ph)2(2) 8.3 Nib 22 41 
FfC-Aca-Phe-Leu-PheP(OPh)2(3) 8.3 9500 16 252 
TXR-Aca-Phe--Leu-Phe"(OPh),(4) 8.3 15 11 96 
Boc-Ala-Ala-Met"(OPh),(5) 210 3 3 2 
Z-Ala-Ala-AlaP(OPh),(6) 41.7 NI 30 38 
Z-Phe--Leu-PheP(Oph),(7) 10.4 110 NI 27 
•Jnbibition kinetics were measured in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer, 5-10% Me2SO 
and at 25° C. 
~o inhibition after 40 min. of incubation of inhibitor and enzyme. No inlu'bition was observed 
with trypsin after one hour of incubation of the enzyme and the inhibitor in 0.1 M Hepes, 0.01 
M CaCI,, pH 7.5. 
Cell Labeling and Imaging. Cells of the NK line RNK-16 
were labeled as live cells, washed, treated with methanol as 
a fixative and permeabilizing agent, and then examined by 
confocal microscopy. The cells were treated at lx107 cells/ 
mL in RPMI 1640 culture media (Sigma Chemical Co., St 
Louis, Mo.) containing 10 mM Hepes with 0.1 mM FfC-
Aca-Ala-Ala-Met1'(0Phh for 30 minutes at 37° C. Control 
cells were treated with the same volume of DMSO required 
to deliver the inhibitor (typically 1 % final concentration). 
Cells were then washed several times with phosphate buff-
ered saline (PBS) to remove excess inhibitor. They were 
suspended overnight in cold 80% methanol to permeabilize 
the membrane. The cells were washed free of MeOH into 
PBS and fixed onto poly-L-lysine (Sigma) coated micro-
scope slides using 3% paraformaldehyde. Fixed slides were 
washed in PBS, coated with Vectashield (Vector 
Laboratories, Inc., Burlingame, Ca.) to prevent fluorescence 
fading and topped with a coverslip. Fluorescent laser scan-
ning confocal microscopy was done with a Bio-Rad MRC 
600 confocal system utilizing a Zeiss Axiophot microscope 
and equipped with a mixed-gas argon/krypton ion laser 
using 488 nm excitation for fiuorescein. 
35 (Diphenyl 1-Aminoalkanephosphonates, Oleksyszyn, J., 
Subotkowska, L., and Mastalerz, P., Synthesis, 1979, 
985-986). For ex~le, H-PheP(OPh)2 , H-Met1'(0Ph)z, 
H-AlaP(OPh)2 , H-Val (0Ph)2 can be prepared by reaction 
of phenylacetaldehyde, 3-(methylthio )propionaldehyde, 
40 
acetaldehyde, 2-methylpropionaldehyde, respectively, with 
triphenylphosphite, benzyl carbamate, and acetic acid to 
give the corresponding Cbz-protected amino acid phospho-
nates (see scheme below) which can be deblocked by 
treatment with HBr/HOAc or hydrogenolysis. Likewise the 
45 
chloro derivative, bis( 4-chlorophenyl) 1-(N-
b en y z y lox y carbonyl amino) - 3 -
methylthiopropanephosphonate, Cbz-Met1'(4-Cl-C6H4 0)2 
can be prepared from tris( 4-chlorophenyl)phosphite, 
benzylcarbamate, and 3-methylthiopropionaldehyde in the 
50 
presence of acetic acid. 
55 
BzIOCONH2 
R-CHO P(OPh)3, HOAc> 
H 0 
I II OPh 
BzIO N p/ y y '-oPh 
0 R 
Fluorescent peptide phosphonates inactivated and labeled 
intracellular granzymes. They traversed the membranes of 
living cells and of their granules and irreversibly labeled the 
cells for subsequent analyses. The inhibitor FTC-Aca-Ala-
Ala-Met1'(0Ph)z reacted with distinct, granule-like regions 60 
of the cytotoxic lymphocytes cell line RNK-16, similar to 
granules as observed in living cells by differential interfer-
ence contrast microscopy. Examination of individual sec-
tions through the cells, indicated that these fluorescent 
regions are interspersed in the cytoplasm. The fluorescent 65 
regions had a granule-like morphology similar to that 
detected by granzyme reactivity with the reversible serine 
Peptide derivatives can then prepared by sequential cou-
pling of N-blocked amino acids using the DCC coupling 
method according to the scheme below. For example H-Phe-
Leu-Phe(OPh)z was prepared by coupling H-PheP(OPh)z 
to Cbz-Leu-OH followed by removal of the Cbz group then 
coupling to Cbz-Phe-OH and finally removal of the protect-
ing group. H-Ala-Ala-AlaP(OPhh and H-Ala-Ala-Met1' 
(0Ph)2 were prepared in the same way by coupling H-AlaP 
(0Ph)2 and H-Met1'(0Ph)2 , respectively to Cbz-Ala-OH 
followed by deblocking, coupling with Cbz-Ala-OH, and 
deblocking. H-Val-Pro-ValP(OPh)2 was prepared from 
5,681,821 
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H-ValP(OPhh by coupling with Cbz-Pro-OH, deblocking, 
coupling with Cbz-Val-OH, and then deblocking. 
H 0 
14 
-continued 
Fluor-Aca-peptide phosphonate 
I II OPh 
BzIO N p/ a) HBr/HOAc ~ 5 Ala-Ala-MetP(QPh)2 FrC-AcA-OH+Ala-Ala-AlaP(OPh)2 --7 
Phe-Leu-PheP(QPh)2 y y 'oPh 
0 R 
b) coupling with blocked 
peptide acid or 
sequential coupling 
with blocked amino 
acid derivatives 
10 
Peptidyl-AAP(OPh), 
Fluorescein- and Texas Red-labeled diphenyl peptidyl 
phosphonate esters are made by joining two intermediates: 
a fiuorophore-e-arninocaproic acid unit and a peptide or 
amino acid phosphonate. Fluorescein isothiocyanate and 15 
Texas Red are coupled to methyl 6-arninocaproate followed 
by saponification of the ester group to give FI'C-Aca-OH 
and TXR-Aca-OH, respectively, see scheme below. Similar 
synthetic routes can be used with other fluorescent groups 
which can be attached to Aca-OMe or other spacer group via 20 
C02H, S03H, NCS, or NCO functional groups. 
FITC 
or 
0 
TXR 
11. H2N(CH2)sCOOMe 
'1r 2. OH-, H3o+ 
NH-CS-NH-(CH2)s-COOH 
or 
0 
1 FrC-Aca-Ala-MetP(QPh)2 
2 FrC-Aca-Ala-AJaP(OPh)2 
3FI'C-Aca-Phe-Leu-PheP(QPh)2 
or 
TXR-Aca-OH+Phe-Leu-PheP(QPh)2 --7 
S02Cl 
4 TXR-Aca -Phe-Leu-PheP(OPh), 
Example of Attachment of the Fluor-Spacer Unit 
to an Amino Acid Phosphonates 
FI'C-Aca-OH TXR-Aca-OH 
Both intermediates can be coupled to the amino acid or 
peptide phosphonate unit using the DCC coupling method as 
shown in the scheme below. 
Examples of Attachment of the Fluor-Spacer Units to 
Peptide Phosphonates 
Fluor-Aca unit+ peptide phosphonate --7 
5,681,821 
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-continued 
0 
II OPh 
p/ 
16 
88%; one spot on TLC (R_,=0.70, CHC13:MeOH:HOAc, 
16:3:1); 1H NMR (DMSO-d6 ) d 10.38-10.05 (m, 3H), 8.32 (bs, lH), 8.24 (s, lH), 7.73 (dd, lH), 7.16 (dd, lH), 
6.70-6.52 (m, 6H), 3.59 (s, 3H), 3.47 (bs, 2H), 2.32 (t, 2H), 
'-oPh 
FTC-Aca-OH+ 
5 1.65-1.50 (m, 4H), 1.40-1.25 (m, 2H); high resolution 
FAB-MS, m/e (M+H) calcd 535.1539; found 535.1560. 
Anal. calcd. for C28H2~207S.H20: C, 60.86; H, 5.11; N, 
5.07; S, 5.80. Found: C, 60.53; H, 5.11; N, 5.05; S, 5.73. 
A solution of lN NaOH (3.0 mL) was added to FTC-
H2 CJ-
(H-(4-ArnPh)GJyP(OPh)z) 
10 Aca-OMe followed by a minimum of MeOH to give a clear 
solution that was stirred at Rf for 1 h. Most of the MeOH 
was removed in vacuo and the aqueous solution was placed 
in an ice bath. Drops of concentrated HCl were added with 
stirring until the mixture became just acidic (pH=3-4). The 
orange suspension that formed was cooled for 3 additional 
lS hours. The solid was isolated by vacuum filtration and dried 
to give FTC-Aca-OH as an orange solid: yield, 95%; one 
spot on TLC (R_,=0.51, CHC13 :MeOH:HOAc, 16:3:1); 1H 
NMR (DMSO-~) d 12.00 (bs, lH), 10.15 (s, 2H), 9.90 (bs, 
lH), 8.30 (s, lH), 8.15 (bs, lH), 7.80 (d, lH), 7.20 (d, lH), 
FTC-Aca-NH 
H2 c1-
20 6.75-6.52 (m, 6H), 3.60-3.40 (bs, 2H), 2.25 (t, 2H), 
1.62-1.48 (m, 4H), 1.42-1.27 (m, 2H); MS (FAB+) m/e 521 
(M+ 1) Anal. calcd. for C27H24N20 7 S.0.5H20: C, 61.24; H, 
4.76; N, 5.29; S, 6.05. Found: C, 61.42; H, 4.58; N, 5.14; S, 
6.00. 
(FTC-Aca-( 4-ArnPH)GJyP(OPh)z) 2S 
The following examples are given to illustrate the invention 
and are not intended to limit it in any manner. 
GENERAL SYNTHESIS PROCEDURES 30 
5-Fluorescein isothiocyanate (FITC), sulforhodamine 
101, 6-aminocaproic acid (Aca), and all common reagents 
and solvents were purchased from Aldrich Chemical 
Company, Milwaukee, Wis. Porcine pancreatic elastase 35 (PPB) was obtained from United States Biochemical Corp., 
Cleveland, Ohio. Human leukocyte elastase (HLE) was 
obtained from Athens Research and Technology, Inc., 
Athens, Ga. Hepes was obtained from Research Organics, 
Inc., Cleveland, Ohio. Bovine trypsin was purchased from 40 
Sigma Chemical Company, St. Louis, Mo. Preparative thin-
layer chromatography was performed with plates precoated 
with 2 mm of silica gel G.F. and were obtained from EM 
Separations, Gibbstown, N.J. 08027. NMR spectra were 
recorded on a Varian GEMINI 300. Elemental analyses were 45 
performed by the Atlantic Microlabs, Atlanta, Ga. Diphenyl 
1-(N-dipeptidylamino )alkanephosphonate esters were syn-
thesized as previously described (Oleksyszyn and Powers, 
Biochemistry, 1991, 30, 485-493). The sulfonyl chloride of 
sulforhodamine 101 (Texas Red) was prepared as previously so 
described (Titus et al., J. Immunol. Methods, 1982, 50, 
193-204) and was used without further isolation in coupling 
reactions. 
EXAMPLE2 
Diphenyl 1-( 6-( 5-Fluoresceinylthiocarbamoylarnino) 
caproylalanylalanylamino )-3-(methylthio) 
propanephosphonate (FTC-Aca-Ala-Ala-Met1'(0Ph) 
2) (General Coupling Procedure) 
FTC-Aca-OH (0.13 g, 0.25 mmol) and the hydrochloride 
of H-Ala-Ala-Met1'(0Phh (0.13 g, 0.25 mmol) were dis-
solved in 25 rnL DMF followed by addition of 1 equivalent 
of TEA. The solution was stirred in an ice bath for 15 min, 
then DCC (0.05 g, 0.25 mmol) was added and the mixture 
was stirred at 0° C. for 4 h and at RT for 48 h. The solvent 
was removed in vacuo and the residue was purified on a 
silica gel column eluted with CHC13 :MeOH (9:1). Fractions 
containing product were combined and concentrated in 
vacuo to give a yellow oil that was triturated with water to 
give a bright yellow solid: yield 25%; 1H NMR (DMSO-d6) 
d 10.15 (s, 2H), 9.95-9.82 (bs, lH), 8.45 (d, lH), 8.25 (s, 
lH), 8.18-7.98 (m, 3H), 7.73 (d, lH), 7.49-7.35 (m, 4H), 
7.30-7.10 (m, 7H), 6.73-6.52 (m, 6H), 4.89-4.67 (m, lH), 
4.42-4.20 (m, 2H), 3.58-3.42 (bs, 2H), 2.72-2.32 (m, 2H), 
2.22-1.92 (m and s, 7H), 1.63-1.42 (m, 4H), 1.38-1.10 (m, 
8H); MS (FAB~ m/e 1004 (M+Na). Anal. calcd. for 
C49H52N50 11PS2.l.5H20: C, 58.32; H, 5.49; N, 6.94; S, 
6.35. Found: C, 58.43; H, 5.72; N, 6.68; S, 6.01. 
FTC-Aca-Met1'(0Phh can be prepared from FTC-Aca-
OH and H-Met1'(0Phh using the same method. FTC-Aca-
Ala-Met1'(0Ph)z can be obtained from the reaction of FTC-
Aca-OH and H-Ala-Met1'(0Ph)z. FTC-Aca-Ala-Ala-Met1' 
(4-Cl-C6H40)2 can also be preparedfromFTC-Aca-OH and EXAMPLE 1 
6-( 5-Fluoresceinylthiocarbamoylamino )caproic acid 
(FTC-Aca-OH) 
5-Fluorescein isothiocyanate (0.20 g, 0.51 mmol) was 
dissolved in 5 mL of DMF. A solution of methyl 
6-aminocaproate (0.15 g, 1.03 mmol) in 1 mL of DMF was 
added at RT, and the mixture was stirred for 0.5 h. The 
solvent was removed in vacuo. The residue was purified on 
ss H-Ala-Ala-Met1'(4-Cl-C6H40)z following the general pro-
cedure. Likewise, FTC-Aca-Ala-Ala-Pro-Met1'(0Ph)2 and 
FTC-Aca-Ala-Ala-Pro-Met!'(4-Cl-C6H40)2 can be prepared 
by the same procedure by coupling FTC-Aca-OH to H-Ala-
Ala-Pro-MetP ( OPh)i and H-Ala-Ala-Pro-MetP( 4-Cl-
60 C6H40)2 , respectively. 
a silica gel column eluted with CHC13:MeOH (4:1). Frac-
tions with R_,=0.38 were collected and concentrated to give 65 
a dark orange oily residue which was triturated with H20 to 
give FTC-Aca-OMe as an orange sheet-like solid: yield 
EXAMPLE3 
Diphenyl 1-( 6-( 5-Fluoresceinylthiocarbamoylarnino) 
caproylalanylalanylarnino) ethanephosphonate 
(FTC-Aca-Ala-Ala-AlaP(OPh)z) 
The general procedure for compound 1 was used, starting 
with H-Ala-Ala-AlaP(OPhh- Crude product was purified on 
5,681,821 
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a silica gel preparative TLC plate using CHC13:MeOH 
(85: 15) as the eluant solvent to give a yellow solid: yield 
35%; 1H NMR (DMSO-d6) d 10.30-10.05 (bs, 2H), 
9.98-9.85 (bs, lH), 8.55 (t, lH), 8.25 (s, lH), 8.18-7.95 (m, 
3H), 7.75 (d, lH), 7.48-7.32 (m, 4H), 7.28-7.08 (m, 7H), 5 
6.75-6.52 (m, 6H), 4.78-4.55 (m, lH), 4.45-4.18 (m, 2H), 
18 
H-Val-Pro-PheP(OPh)i, and FfC-Aca-Val-Pro-PheP(4-Cl-
C6H40)2 can be prepared following the same procedure 
from FTC-Aca-OH and H-Val-Pro-PheP(4-Cl-C6H40)i. 
EXAMPLE 5 
3.58-3.38 (m, 2H), 2.12 (t, 2H), 1.62-1.05 (m, 15H); MS Diphenyl 1-(6-(5-fluoresceinylthiocarbamoylamino) 
(FAB+) m/e 921 (M). Anal. calcd. for C47H4gN5Q11PS.H2Q: caproylamino)(4-amidinophenyl) 
C, 60.06; H, 5.37; N, 7.50; S, 3.40. Found: C, 60.04; H, 5.35; methanephosphonate (FTC-Aca-(4-AmPh)Gly1' 
N, 7 36; S, 3.39. 10 (OPh)i) 
Using the same procedure, FfC-Aca-AlaP(OPh)2 and FfC-Aca-OH (0.20 g, 0.38 mmol), (4-AmPh)Gly(OPh) 
FfC-Aca-Ala-AlaP(OPh)i can be prepared from FfC-Aca- 2.HCl (0.19 g, 0.42 mmol) were dissolved in 10 mL of DMF 
OHandH-AlaP(OPh)iandH-Ala-AlaP(OPhh,respectively. in a 25 mL round bottom flask. N-methylmorpholine 
FfC-Aca-Ala-Ala-AlaP( 4-Cl-C6H40h can also be prepared (NMM) (0.05 mL) was added to the flask followed by HOBt 
from the reaction of FfC-Aca-OH and H-Ala-Ala-AlaP 15 (0.05 g, 0.38 mmol). The flask was cooled in an ice bath for 
(Ophh, FfC-Aca-Ala-Ala-ValP(OPh)i can be prepared 15 min then DCC (0.08 g, 0.38 mmol) was added and the 
from FfC-Aca-OH and H-Ala-Ala-ValP(Oph)2, FfC-Aca- mixture was stirred in ice for 5 h and at Rf for 48 h. The 
Ala-Ala-ValP(4-Cl-C6H40)2 can be obtained from the reac- solvent was removed in vacuo and the residue was purified 
tion between FfC-A;:a-OH and H-Ala-Ala-ValP(OPh)i, on a silica gel preparative plate using CHC13:MeOH:HOAc 
FfC-Aca-Val-Pro-Val (OPh)i can be prepared from FfC- 20 (16:6:1). The product was isolated as a yellow oil that was 
Aca-OH and H-Val-Pro-ValP(Ophh, FfC-Aca-Val-Pro- dissolved in saturated HCl in ethyl acetate The solvent was ValP(4-Cl-C~40)i can be preparedfromFfC-Aca-OH and removed immediately after dissolution and the residue was 
H-Val-Pro-ValP(4-Cl-C6H40)i, FfC-Aca-Ala-Ala-NvaP then triturated with hexane to give a yellow solid: yield 
(0Ph)2 can be ;repared from coupling FfC-AcafH to 15-20%; TLC, major spot (R_r().44, CHC13:MeOH:HOAc, 
H-Ala-Ala-Nva (OPh)2, and FfC-A~-Ala-Ala-Nva (4-Cl- 25 16:6:1); the 1H NMR spectrum is consistent with the struc-
C6H40)2 can ~ prepared by coupling FfC-Aca-OH to ture of this compound and it showed the presence of some 
H-Ala-Ala-Nva (4-Cl-C~40)i. impurities; MS (FAB+) m/e 884 ((M-HCl)+l). Anal. calcd. 
EXAMPLE 4 for C47H43N50 9ClPS.5H20: C, 55.87; H, 5.28; N, 6.93; S, 
3.17. Found: C, 56.25; H, 5.47; N, 732; S, 338. 
Diphenyl 1-(6-(5-Fluoresceinylthiocarbamoylamino) 30 Using the same procedure FfC-Aca-(4-AmPh)Gly1'(4-
caproylphenylalanylleucylamino )-2- Cl-C6H40)i be prepared from the reaction of FfC-Aca-OH 
phenylethanephosphonate (FTC-Aca-Phe-Leu-PheP and H-( 4-AmPh)Gly1' ( 4-Cl-C6H40)2 , FfC-Aca-Pro-( 4-(0Ph)i) AmPh)Gly(OPhh can also be prepared following this 
The general procedure for compound 1 was used, starting 35 procedure from FfC-Aca-OH and H-Pro-( 4-AmPh)Gly1' 
with H-Phe-Leu-PheP(OPh)i. Yield36%; 1H NMR (DMSO- (OPh)i, FfC-Aca-Phe-Pro-(4-AmPh)Gly1'(0Ph)2 can be 
d6) d 10.15 (s, 2H), 9.85 (bs, lH), 8.87 (d, lH), 8.77 (d, lH), obtained from the reaction between FfC-Aca-OH and 
8.25 (s, lH), 8.10-7.90 (m, 3H), 7.75 (d, lH), 7.45-7.05 (m, H-Phe-Pro-(4-AmPh)Gly1'(0Ph)i, FfC-Aca-Phe-Phe-(4-
21H), 6.72-6.52 (m, 6H), 4.92-4.75 (m, lH), 4.62-4.32 (m AmPh)Gly1'(0Phh can be obtained from coupling FfC-
and m, 2H), 3.50-2.5S (m, 6H), 2.09-1.92 (m, 2H), 40 Aca-OH to H-Phe-Phe-(4-AmPh)Gly1'(0Ph)2, FfC-Aca-
1.60-0.90 (m, 9H), 0.85-0.65 (m, · 6H); MS (FAB+) m/e Ar~(OPh)2 can be prepared from the reacti~n of FfC-Aca-
389.9 (100%, M+-fluoresceinyl-NHCS), 1116 (20%, M+l). OH and H-Ar~(OPh)2, and FfC-Aca-Lys (OPh)i can be 
Anal. calcd. for C62H62N5Q11PS.H20: C, 65.66; H, 5.69; N, prepar;;d using the same procedure from FfC-Aca-OH and 
6.17; S, 2.82. Found: C, 65.98; H, 5.68; N, 6.21; S, 2.80. H-Lys (OPh)2· 
EXAMPLE6 
6-(4(or 2)(9-(2,3,6,7,12,13,16,17-octahydro-lH,5H, 
11H,15H-xantheno(2,3,4-ij:5,6,7-i]')diquinolizinyl-
18-ium))3( or 5)-sulfo-1-phenylsulfonamido )caproic 
Acid, Hydroxide, Inner Salt (TXR-Aca-OH) 
The intermediate TXR-Aca-OMe was synthesized from a 
freshly prepared dry Texas Red solution in CHC13 (Titus et 
al., 1982) and 1 equivalent of 6-aminocaproic acid methyl 
ester in the presence of 1 equivalent NMM. After stirring at 
0° C. for 0.5 h and at Rf overnight, the mixture was 
concentrated in vacuo to give a dark solid that was purified 
on a silica gel preparative plate using CHC13:MeOH:HOAc (16:3:1) to give TXR-Aca-OMe: yield, 67%; one spot on 
FfC-Aca-PheP(OPhh can be obtained from the reaction 45 
of FfC-Aca-OH and H-PhP(OPhh using the procedure 
above. FfC-Aca-Pro-PheP(Oph}i and FfC-Aca-Leu-PheP 
(OPh)i can also be prepared from coupling FfC-Aca-OH 
with H-Pro-PheP(OPhh and H-Leu-PheP(OPh)i, respec-
tively. FfC-Aca-Phe-Leu-PheP(4-Cl-C6H40h can be pre- 50 
pared following the same procedure from FfC-Aca-OH and 
H-Phe-Leu-PheP(4-Cl-C6H40)2, FfC-Aca-Ala-Ala-Ala-
PheP(OPhh can also be prepared by the coupling of FfC-
Aca-OH and H-Ala-Ala-Ala-Phe(OPh)2, FfC-Aca-Ala-
Ala-Ala-PheP( 4-Cl-C6H40)2 can be obtained from the 55 
reaction of FfC-Aca-OH and H-Ala-Ala-Ala-PheP(4-Cl-
C6H40)i, FfC-Aca-Ala-Ala-Pro-Phe(OPhh can be pre-
pared from the reaction of FfC-Aca-OH and H-Ala-Ala-
Pro-PheP(Oph)i, FfC-Aca-Ala-Ala-Pro-PheP(4-Cl-
C6H40)i can be prepared from the reaction of FfC-Aca-OH 
and H-Ala-Ala-Pro-PheP(4-Cl-C6H40h, the procedure 
described above can also be used to prepare FfC-Aca-Phe-
Pro-Phe (Oph)i from FfC-Aca-OH and H-Phe-Pro-PheP 
(0Ph)2 , FfC-Aca-Phe-Pro-PheP(4-Cl-C6H40)2 can be 
obtained from the reaction of FfC-Aca-OH and H-Phe-Pro- 65 
PheP(4-Cl-C6H40)i, FfC-Aca-Val-Pro-Phe (OPhh can be 
obtained from the reaction between FfC-Aca-OH and 
60 TLC (R;=0.71, CHCl3:MeOH:HOAc, 16:3:1); 1H NMR 
(DMSO-d6) d 8.42 (d, lH), 7.98-7.85 (m, 2H), 7.35 (d, lH), 
6.52 (s, 2H), 3.60-3.40 (sand m, llH), 3.05-2.95 (m, 4H), 
2.92-2.80 (m, 2H), 2.67-2.55 (m, 4H), 2.27 (t, 2H), 
2.11-1.75 (m, 8H), 1.55-1.18 (m, 6H); high resolution 
FAB-MS, m/e (M+H) calcd. 734.2570; found 734.2568. 
Anal. calcd. for C38H43N30 8S2.2.5H20: C, 58.60; H, 6.21; 
N, 5.39; S, 8.23. Found: C, 58.41; H, 5.83; N, 5.33; S, 8.09. 
5,681,821 
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Val-Pro-PheP(4-Cl-C6H40h can be prepared from the reac-
tion between TXR-Aca-OH and H-Val-Pro-PheP(4-Cl-
C6H40h, TXR-Aca-Ala-Ala-AlaP(OPh)z can be obtained 
from coupling TXR-Aca-OH to H-Ala-Ala-AlaP(OPh)z, 
An excess solution of lN NaOH was added to TXR-Aca-
OMe followed by a few drops of MeOH. The mixture was 
stirred at RT for 2 h, then cooled in an ice-bath. Concentrated 
HCl was added carefully until a dark solid completely 
precipitated. The solid was isolated by vacuum filtration and 
then purified on a preparative plate to give TXR-Aca-OH: 
yield, 85%; one spot on TLC (R_r=0.55, 
CHC13:MeOH:HOAc, 16:3:1); 1H NMR (DMSO-d6) d 8.40 
5 TXR-Aca-Ala-Ala-Metp(OPhh can also be prepared from 
the reaction of TXR-Aca-OH with H-Ala-Ala-Metp(OPh)z, 
and TXR-Aca-(4-AmPh)Gly(OPh)z can be prepared fol-
lowing the same procedure from the reaction between TXR-
Aca-OH and H-(4-AmPh)Gly(OPhh (d, lH), 8.05-7.88 (m, 2H), 7.37 (d, lH), 6.50 (s, 2H), 
3.60-3.40 (m, SH), 3.05-2.95 (m, 4H), 2.90-2.80 (m, 2H), 10 
2.68-2.58 (m, 4H), 2.10-1.95 (m, 6H), 1.90-1.78 (m, 4H), 
1.50-1.15 (m, 6H); high resolution FAB-MS m/e (M+H) 
calcd. 720.2435; found 720.2413. 
EXAMPLE? 
Diphenyl 1-(6-(4(or 2)(9-(2,3,6,7,12,13,16,17-
octahydro-lH,5H,llH,l5H-xantheno(23,4-ij:5,6,7-
i'j')diquinolizinyl-18-ium))3( or 5)sulfo-1-
phenylsulfonamido) 
caproylphenylalanylleucylamino )-2-
phenylethanephosphonate, Hydroxide, Inner Salt 
(TXR-Aca-Phe-Leu-PheP(OPh)2) 
This compound was prepared from TXR-Aca-OH (0.084 
15 
20 
g, 0.12 mmol) and H-Phe-Leu-PheP(OPh)2 hydrochloride 25 
(0.084 g, 0.13 mmol) using the DCC/HOBt method in the 
presence of TEA. The reaction was carried out in CHC13 at 
0° C. for 2 h and at RT for 48 h. The crude product was 
purified on a silica gel preparative TLC plate using 
CHC13 :MeOH:AcOH (16:3:1) as the eluting solvent. The 30 
isolated product was dissolved in 20 mL CHC13 and 
extracted twice with 10 mL of 5% aqueous NaHC03 then 
with 10 mL H20. The organic layer was dried (Na2S04) and 
then concentrated to give a dark purple solid: yield, 25-35%; 
one spot on TLC, Rr0.79, CHC13 :MeOH:AcOH (16:3:1); 35 
NMR spectrum was recorded and was consistent with the 
proposed structure; high-resolution FAB-MS, m/e (M+H) 
calcd. 1315.501; found 1315.495. Anal. calcd. for 
C72H79N601~S2.2H20: C, 63.98; H, 6.18; N, 6.22; S, 4.74. 
Found: C, 63.62; H, 6.03; N, 6.39; S, 4.87. 40 
This procedure can be used to prepare TXR-Aca-AlaP 
(OPh)z, TXR-Aca-Metp(OPh)2, TXR-Aca-Phe(OPh)z, and 
TXR-Aca-(4-AmPh)Gly(OPh)2 from coupling TXR-Aca-
OH with H-AlaP(OPh)2, H-Metp(OPh)z, H-PheP(OPh)z, 
and H-(4-AmPh)Gly(OPh)z, respectively. Likewise TXR- 45 
Aca-Pro-PheP(OPhh and TXR-Aca-Pro-PheP(OPh)z can be 
prepared from coupling TXR-Aca-OH with H-Pro-PheP 
(0Ph)2 and H-Leu-PheP(OPh)2, respectively. TXR-Aca-
Ala-Me~(OPh)z can be obtained from the reaction between 
TXR-Aca-OH and H-Ala-Metp(OPhh TXR-Aca-Phe-Leu- 50 
Phe(4-Cl-C6H40)z can be prepared from TXR-Aca-OH 
and H-Phe-Leu-PheP(4-Cl-C6H40)2, TXR-Aca-Ala-Ala-
Ala-PheP(OPh)z can be obtained from the reaction between 
TXR-Aca-OH and H-Ala-Ala-Ala-PheP(OPh)2, TXR-Aca-
Ala-Ala-Ala-PheP(4-Cl-C6H40)2 can also be prepared from 55 
the reaction of TXR-Aca-OH and H-Ala-Ala-Ala-Phe(4-
Cl-C6H40)z, TXR-Aca-Ala-Ala-Pro-PheP(OPh)z can be 
obtained from coupling TXR-Aca-OH to H-Ala-Ala-Pro-
PheP(OPh)2, TXR-Aca-Ala-Ala-Pro-PheP(4-Cl-C6H40)2 
can be prepared from the reaction between TXR-Aca-OH 60 
and H-Ala-Ala-Pro-PheP(4-Cl-C6H40)z, TXR-Aca-Phe-
Pro-PheP(OPh)z can be obtained from the reaction between 
TXR-Aca-OH and H-Phe-Pro-PheP(OPh)z, TXR-Aca-Phe-
Pro-PheP(4-Cl-C6H40)z can also be obtained from coupling 
TXR-Aca-OH to H-Phe-Pro-PheP(4-Cl-C6H40)z, TXR- 65 
Aca-Val-Pro-Phe(OPhh can be prepared by this procedure 
from TXR-Aca-OH and H-Val-Pro-PheP(OPh)2, TXR-Aca-
What is claimed is: 
1. A compound of the formula: 
R 
l oz Floor-T-Spacer-AA3-AA2-~ p/ 
H 11'-ozi 
0 
or an acceptable salt, wherein 
Fluor is selected from the group consisting of 
HO 0 
(5-Substitued Fluorescein) 
HO 0 
( 6-Substituted Fluoresce in) 
(5-Substituted Tetramethylrhodamine) 
(CH3 
( 6-Substituted Tetramethylrhodamine) 
(a) 
(b) 
(c) 
(d) 
5,681,821 
21 
-continued 
(e) 
5 
10 
(5-Substituted Texas Red) 
(f) 15 
22 
glycine, alanine, valine, leucine, isoleucine, proline, 
methionine, methionine sulfoxide, methionine 
sulfone, phenylalanine, tryptophan, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, 
alpha-arninobutyric acid, citrulline, hydroxyproline, 
ornithine, and homoarginine, and 
(b) phenyl substituted with B, benzyl substituted with 
B on the phenyl, 
B is selected from the group consisting of amidino 
(-C(=NH)NH2), guanidino (-NH-C( NH) 
NH2), isothiureido (-S-C(=NH)NH2), and 
amino, 
Z and Z1 are the same or different and are selected 
independently from the group consisting of phenyl, 
phenyl substituted with J, phenyl disubstituted with J, 
and phenyl trisubstituted with J, and 
20 J is selected from the group consisting of halogen, C1_6 
25 
(6-Substituted Texas Red) 
and 
(g) an aromatic fluorescent group with an emission 
maximum of 350 to 700 run, 30 Y is selected from the group consisting of H, COOH, 
and S03H, 
Tis selected from the group consisting of -NH-CO-, 
-NH-CS-, -CO-, and -S02-, 
Spacer is selected from the group consisting of 
(a) a single bond, 
(b) -NH-CH2-CH2-CH2-CH2-CH2-CO-, 
35 
( c) -NH-CH2-CH2-CH2-CH2-CH2-CO-
NH-CH2-CH2-CH2-CH2-CH2-CO-, 
( d) an organic structure which is 3-24 A long and 
including a backbone comprising at least one mem- 40 
ber of the group consisting of -CH2-CH2-, 
-CO-NH-, -NH-CO-, -CH2-CO-, 
-CH2-NH-, -NH-CH2-, and -C6H4-, 
AA3 and AA2 are the same or different and are selected 
independently from the group consisting of 
(a) a single bond, 
45 
(b) a side chain blocked or unblocked amino acid 
residue with the L or D configuration at the a-carbon 
selected from the group consisting of alanine, valine, 
leucine, isoleucine, proline, methionine, methionine 50 
sulfoxide, methionine sulfone, phenylalanine, 
tryptophan, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, 
norleucine, norvaline, alpha-arninobutyric acid, 55 
citrulline, hydroxyproline, ornithine, and 
homoarginine, and 
(c) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, 
R is selected from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
side chain selected from the group consisting of 
60 
alkyl, C1--{j perfluoroalkyl, C1--{j alkoxy and CN. 
2. A compound according to claim 1 wherein 
Fluor is the structure 
0. 
3. A compound according to claim 2 wherein 
Yis COOH, 
T is selected from the group consisting of -NH-CS-
and -NHCO-, 
Spacer is -NH-CH2-CH2-CH2-CH2-CH2 -
CO-, 
AA3 and AA2 are the same or different and are selected 
independently from the group consisting of 
(a) a single bond, 
(b) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, methionine, phenylalanine, and proline, 
R is selected from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
residue selected from the group consisting of 
alanine, valine, leucine, isoleucine, methionine, 
phenylalanine, aspartic acid, lysine, arginine, and 
phenylglycine, 
(b) a phenyl group substituted with B, 
B is amidino, and 
Z and Z1 are the same or different and are selected 
independently from the group consisting of phenyl or 
phenyl substituted with a halogen. 
4. A compound according to claim 1 wherein 
5,681,821 
23 
Fluor is the structure 
5. A compound according to claim 4 wherein 
Yis S03 H, 
T is selected from the group consisting of ---S02- and 
-NHCS-, 
Spacer is -NH-CH2-CH2-CH2-CH2-CH2-
5 
10 
15 
24 
(a) a single bond, 
(b) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, methionine, phenylalanine, and proline, 
R is selected from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
side chain selected from the group consisting of 
alanine, valine, leucine, isoleucine, methionine, 
phenylalanine, aspartic acid, lysine, arginine, and 
phenylglycine, 
(b) a phenyl group substituted with B, 
B is amidino, and 
Z and Z1 are the same or different and are selected 
independently from the group consisting of phenyl or 
phenyl substituted with a halogen. 
CO-, 20 
AA3 and AA 2 are the same or different and are selected 
independently from the group consisting of 
6. A compound or an acceptable salt of the compound 
selected from the group of structures consisting of 
(a) 
HO 
(FTC-Aca-Ala-Ala-AJaP(OPh)2) 
(b) 
(FTC-Aca-Ala-Ala-MetP(OPh)2) 
(c) 
HO 
(FTC-Aca-Phe-Leu-PheP(OPh)2) 
5,681,821 
25 26 
-continued 
NH-CS-NH-CH2-CH2-CH2-CH2-CH2-C0-(4-AmPh)GlyP(OPh)z 
(d) 
HO 0 
(FTC -Aca-(4-AmPh)GlyP(OPh)z) 
S02-NH-CH2-CH2-CH2-CH2-CH2-CO-Phe-Leu-PheP(OPh)z 
(e) 
(I'XR-Aca-Phe-Leu-PheP(OPh)z). 
7. A compound according to claim 1 wherein AA3 is a side 30 
chain unblocked amino acid residue with the L configuration 
at the a-carbon. 
8.Acompoundaccordingto claim 1 whereinAA3 is a side 
chain unblocked amino acid residue with the D configura-
tion at the a-carbon. 35 
9. A compound according to claim 1 wherein AA 3 is a side 
chain blocked amino acid residue with the L configuration at 
the a-carbon. 
10. A compound according to claim 1 wherein AA3 is a 
side chain blocked amino acid residue with the D configu- 40 
ration at the a-carbon. 
11. A compound according to claim 1 wherein AA 2 is a 
side chain unblocked amino acid residue with the L con-
figuration at the a-carbon. 
12. A compound according to claim 1 wherein AA 2 is a 45 
side chain unblocked amino acid residue with the D con-
figuration at the a-carbon. 
13. A compound according to claim 1 wherein AA 2 is a 
side chain blocked amino acid residue with the L configu-
ration at the a-carbon. 
14. A compound according to claim 1 wherein AA 2 is a 
side chain blocked amino acid residue with the D configu-
ration at the a-carbon. 
15. A compound according to claim 1 wherein AA3 and 
AA 2 are the same. 
16. A compound according to claim 1 wherein AA3 and 
AA 2 are different 
17. A compound according to claim 1 wherein Zand Z1 
are the same. 
18. A compound according to claim 1 wherein Z and Z1 
are different. 
19. A method for detecting the presence of a serine 
protease in cells, plasma, or other biological media, com-
prising contacting the serine protease with a compound 
according to claim 1. 
20. A method for inhibiting a serine protease that is 
present in cells, plasma, or other biological media, compris-
ing contacting the serine protease with a compound accord-
ing to claim 1. 
* * * * * 
